Against HSCT in Ph-positive ALL

Share :
Published: 18 Oct 2018
Views: 2425
Prof Robin Foa - Professor of Haematology and Head of Haematology, University of Rome, Rome, Italy

Prof Robin Foa talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about targeted treatments that are an alternative to HSCT in Ph-positive ALL.

Prof Foa outlines that we have learned that we are able treat to chronic myeloid leukaemia and Philadelphia-like ALL with tyrosine kinase inhibitors.

He understands that the evidence lacks a large randomised study, as it is a sub group of a rare disease.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.